Scarica l'app Stockscreener
76.84
0.58%
0.44
Dopo l'orario di chiusura:
76.91
0.07
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Merck Co Inc Borsa (MRK) Ultime notizie
Merck & Co., Inc. (MRK)’s MK-1084 Shows Promise in Early Cancer Trial - Insider Monkey
Merck & Co., Inc. (MRK) Reports Positive Trial Results for DLBCL Drug - Insider Monkey
ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small - insights.citeline.com
Jim Cramer on Merck & Co (MRK): ‘I’ve Got To Take a Hard Look At It’ - MSN
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers - Benzinga
Merck (MRK) Sees Promising Results in Cancer Drug Trial - GuruFocus
Merck releases positive early-stage data on colorectal cancer and NSCLC asset - Seeking Alpha
Merck (MRK) Antibody Drug Shows Promise in Lymphoma Trial - GuruFocus
Merck antibody drug conjugate asset shows antitumor activity in phase 2 - Seeking Alpha
Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - MSN
Merck Reports Antitumor Activity With Experimental KRAS Inhibitor MK-1084 in Early Trial - marketscreener.com
Merck Says Potential Lymphoma Therapy Achieves 56.3% Response Rate in Phase 2 Study - marketscreener.com
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor - marketscreener.com
Merck (MRK) Reports Promising Phase 2/3 Trial Results for Cancer Therapy | MRK Stock News - GuruFocus
Merck reports promising results for cancer drug MK-1084 By Investing.com - Investing.com India
Merck reports promising DLBCL treatment results By Investing.com - Investing.com India
Here’s Why Merck & Co. (MRK) Traded Lower in Q1 - Insider Monkey
Merck reports promising DLBCL treatment results - Investing.com
Merck'S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity - marketscreener.com
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial - Business Wire
Merck’s West Point Presence Remains Strong Amid Riverside Closure - bucksco.today
Transcript : Merck & Co., Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 03 - marketscreener.com
Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - Yahoo Finance
Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS - insights.citeline.com
Merck & Co To Present At Bernstein Strategic Decisions Conference; Webcast At 3:30 PM ET - Nasdaq
Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer - Reuters
Merck & Co. Concludes Annual Shareholders Meeting - TipRanks
Merck shareholders approve board, executive pay at annual meeting By Investing.com - Investing.com India
Merck shareholders approve board, executive pay at annual meeting - Investing.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Merck, Daiichi pull approval application for ADC in lung cancer - BioPharma Dive
Merck: voluntary withdrawal of a BLA in lung cancer - marketscreener.com
Is Merck Stock Underperforming the Nasdaq? - MSN
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck (MRK) and Daiichi Sankyo Withdraw U.S. Application for Lung Cancer Therapy - GuruFocus
Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw - marketscreener.com
Is Merck Stock Underperforming The Nasdaq? - Barchart.com
Merck (MRK) Withdraws Biologics License Application for Patritum - GuruFocus
Merck stock drops as BLA for lung cancer drug is pulled (MRK) - Seeking Alpha
Merck Withdraws Biologics License Application for Patritumab Deruxtecan - marketscreener.com
Major Setback: Merck's Advanced Lung Cancer Drug Falls Short in Crucial Survival Trial - Stock Titan
Abbisko Secures $85 Million from Merck for Pimicotinib Global Rights - TipRanks
Dow falls nearly 250 points on losses in Merck, Nike shares - MSN
Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market | DelveInsight - PR Newswire UK
Merck Votes Overwhelmingly in Support of DEI Amid Backlash - Sustainability Magazine
Merck Proves Why It’s Still A Top Pharma Pick (NYSE:MRK) - Seeking Alpha
Merck (MRK) Options Activity Highlights Bullish Sentiment | MRK Stock News - GuruFocus
Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2025, Payable on July 8, 2025 - marketscreener.com
Merck sets $0.81 quarterly dividend for Q3 2025 By Investing.com - Investing.com India
Merck Announces Third-Quarter 2025 Dividend - BioSpace
Merck Announces Third-Quarter 2025 Dividend Of $0.81 Per Share - marketscreener.com
NLPC Warns Merck About ‘Materially Misleading’ Shareholders on DEI - National Legal And Policy Center
Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors - GlobeNewswire Inc.
Merck & Co.’s SWOT analysis: stock faces keytruda LOE, china challenges - Investing.com
Merck Issues Statement On Potential Reduced Dosing Recommendation For Gardasil 9 - marketscreener.com
Merck: Dividend Near A 12-Year High, But I Won't BuyHere's Why (NYSE:MRK) - Seeking Alpha
Merck: Defensive Yield Meets Long-Term Optionality - Seeking Alpha
Merck (MRK) Advises Against Changing Gardasil Dosing Schedule - GuruFocus
Merck contends single dosing of Gardasil vaccine should be avoided - Seeking Alpha
Merck (MRK) Stands Firm on Gardasil 9 Dosing Standards | MRK Stock News - GuruFocus
Merck & Co., Inc. (MRK): A Bull Case Theory - MSN
Merck: Undervalued In Light Of Key Risks (NYSE:MRK) - Seeking Alpha
Merck & Co. Stock: Inventory Doesn’t Lie (NYSE:MRK) - Seeking Alpha
July 3rd Options Now Available For Merck (MRK) - Nasdaq
2.58%
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):